Search Results
Your search for it matches 15756 pages
Showing 10501 - 10550AUA 2016: Relationship Between Testosterone Therapy and Prostate Cancer Explored
Men with low levels of the male sex hormone testosterone need not fear that testosterone replacement therapy will increase their risk of prostate cancer. This is the finding of an analysis of more than a quarter-million medical records of mostly white men in Sweden, research led by investigators at ...
Hormone Combination Therapy May Increase Risk of Breast Cancer in African American Women
The use of combination therapy with estrogen plus progestin, previously shown to be associated with an increased incidence of estrogen receptor–positive breast cancer in postmenopausal women in studies based largely on white women, has been shown to increase estrogen receptor–positive breast cancer ...
Some Diagnostic Variability in Interpreting Breast Biopsy Slides
Pathologists disagree about 8% of the time when interpreting a single breast biopsy slide, with more overinterpretation than underinterpretation in discordant cases, according to an analysis combining results from the B-Path (Breast Pathology) study with data on the prevalence of breast cancer...
Improved Survival With Shorter Delays Between Diagnosis and Surgery and Before Initiating Adjuvant Chemotherapy
The survival benefits of reducing the time to surgery following a diagnosis of breast cancer and the time to initiation of adjuvant chemotherapy following surgery were outlined in two articles and an accompanying editorial in JAMA Oncology. Analyzing two independent population-based studies with a...
Corporate Angel Network’s 50,000th Patient Flight Benefits Young Retinoblastoma Patient
On April 14, 2016, an 18-month-old patient with cancer named Baron Yerby flew home to Atlanta after receiving treatment at Memorial Sloan Kettering Cancer Center. However, instead of flying on a crowded commercial plane with the potential for immune deficiency issues, he and his parents flew on a...
Cancer Stole My Identity
In 1997, just 6 weeks after giving birth to my second child, I started having fevers and night sweats and my lymph nodes were swollen. I’m a physician, so I knew something was wrong and that my symptoms were unrelated to having just given birth. I had a blood test, and a biopsy was performed on one ...
The Parker Foundation Launches the Parker Institute for Cancer Immunotherapy With a $250 Million Grant
On April 13, The Parker Foundation announced a $250 million grant to launch the Parker Institute for Cancer Immunotherapy, a collaboration between scientists, clinicians, and industry partners to lead an unprecedented cancer immunotherapy research effort. The gift is the largest single contribution ...
‘So How Long Do I Have?’
Imagine accidentally falling off an abyss. One simply cannot fully understand the gravity of the situation! You might skip a beat thinking about it while sitting in a chair in your living room, if you have tons of empathy, as you try to get into the shoes that are flailing for survival. But there...
A History of Medical Care for the Dying
In 2006, palliative care became a board-certified subspecialty of internal medicine, with specialized fellowships for physicians interested in the field. Despite its formal integration into best practices medical care, about 70% of Americans describe themselves as “not at all knowledgeable” about ...
Inspirational Stories for Cancer Survivors
Surveys indicate that cancer survivors have varying desires regarding the kind of support they want. Some patients find support groups very helpful as they deal with the host of issues in survivorship. Others want to distance themselves from the “world of cancer.” Studies also show that...
FDA Launches First Campaign Focused on Dangers of Smokeless Tobacco Among Rural Teens
The U.S. Food and Drug Administration (FDA) has announced it is expanding its award-winning “The Real Cost” campaign to educate rural white male teenagers about the negative health consequences associated with smokeless tobacco use. For the first time, messages on the dangers of smokeless tobacco...
Breakthrough Therapy Efforts Result in Unprecedented Success
Friends of Cancer Research (Friends) and the U.S. Food and Drug Administration (FDA) have been working together for many years on an idea known as breakthrough therapy, and it has produced results beyond anyone’s hopes. Said Ellen Sigal, PhD, Friends Chair and Founder, “When we were first talking...
Clinical Trials Actively Recruiting Patients With Ewing Sarcoma
Phase I Study Title: A Phase I Study to Examine the Toxicity of Allogeneic Stem Cell Transplantation for Relapsed or Therapy-Refractory Ewing Sarcoma Study Type: Interventional/nonrandomized/single-group assignment Study Sponsor and Collaborators: University of Louisville Purpose: To examine the...
Expert Point of View: Julie Margenthaler, MD and Mahmoud El-Tamer, MD
Press briefing moderator Julie Margenthaler, MD, of Washington University Siteman Cancer Center, St. Louis, who is Communications Committee Chair for the American Society of Breast Surgeons, agreed that surveillance would be acceptable only within a clinical trial, and one is underway now....
Sheldon M. Feldman, MD, Named President of ASBrS
Sheldon M. Feldman, MD, was named President of the American Society of Breast Surgeons (ASBrS) at the organization’s 2016 Annual Meeting in Dallas, Texas. Dr. Feldman is the Chief of Breast Surgery at NewYork-Presbyterian/Columbia University Medical Center and the Vivian L. Milstein Associate...
Redesigned ASCO.org Launches With Improved Usability
ASCO launched a new and improved website in early April, with a focus on improving the user experience. The Society’s redesigned online home makes it easier than ever for members and visitors to find the oncology-related information and resources they trust and value. The site’s redesign is the...
AUA 2016: Adjuvant Chemotherapy After Radical Prostatectomy May Benefit Men at High Risk for Relapse
Not all men with prostate cancer benefit from adjuvant chemotherapy after radical prostatectomy; however, African American men and men with a higher tumor stage may, according to a new U.S. Department of Veterans Affairs (VA) study (Abstract PI LBA 06) featured at the 111th Annual Scientific...
Defibrotide Sodium for Hepatic Veno-occlusive Disease After HSCT
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On March 30, 2016, defibrotide sodium (Defitelio) was approved for...
Shedding Light on a Cornucopia of Breast Tumor Biomarker Assays
As our understanding of the complexities of breast cancer expands, so does our treatment armamentarium—and along with it the range of factors that must be included in our treatment decisions. Gone is the simple algorithm of adjuvant chemotherapy for almost every patient with a ≥ 2-cm tumor, except...
ASCO Guideline on Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy in Early-Stage Invasive Breast Cancer
As reported in the Journal of Clinical Oncology by Lyndsay N. Harris, MD, and colleagues,1 ASCO has released a clinical practice guideline on the use of biomarkers in addition to estrogen receptor/progesterone receptor and HER2 status to guide decisions on adjuvant systemic therapy in women with...
Moving Forward in Castration-Resistant Prostate Cancer: The TERRAIN and STRIVE Studies
It was over 2 decades ago that my colleagues and I reported in The New England Journal of Medicine that a first-generation oral antiandrogen, flutamide, when added to a luteinizing hormone–releasing hormone (LHRH) agonist, improved survival by nearly 6 months compared to an LHRH agonist alone in...
Breaking Down Dogma With the Outgoing President of SGO
At the 2016 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer, The ASCO Post sat down with the SGO’s outgoing President, Robert L. Coleman, MD, and discussed the revolutionary potential of blood biomarkers, why enhanced recovery after surgery protocols is a significant...
Roundup of Ovarian Cancer Abstracts From 2016 SGO Annual Meeting on Women’s Cancer
At the 2016 Society of Gynecologic Oncology’s (SOG’s) Annual Meeting on Women’s Cancer, Thomas J. Herzog, MD, Clinical Director, University of Cincinnati (UC) Cancer Institute and Professor of Obstetrics and Gynecology at UC College of Medicine, provided commentary on several noteworthy ovarian...
Expert Point of View: Gini Fleming, MD
In the discussion session, Gini Fleming, MD, Professor of Medicine and Director of the Gynecologic Oncology and Medical Oncology Breast Program at the University of Chicago Medical Center, analyzed the three previous, large trials on which the presumed benefits of intraperitoneal therapy in women...
Intraperitoneal Chemotherapy in Question in Ovarian Cancers
A phase III trial of bevacizumab (Avastin) with intravenous vs intraperitoneal chemotherapy showed no improvement in progression-free survival for first-line treatment of patients with optimally surgically resected stage II and III ovarian, peritoneal, or fallopian tube cancer.1 When compared with...
Expert Point of View: Harold Burstein, MD, PhD
Invited discussant Harold Burstein, MD, PhD, Associate Professor of Medicine at Harvard Medical School and a medical oncologist at Dana-Farber Cancer Institute and Brigham & Women’s Hospital, Boston, called MINDACT “a heroic effort” whose results show that combining stage, pathology, and...
First Results From MINDACT Confirm the Benefit of Genomic Profiling
The primary analysis of the MINDACT trial confirms the value of genomic profiling for patients with early breast cancer with zero to three positive lymph nodes, according to MINDACT investigators and breast cancer specialists who heard the results at the 2016 American Association of Cancer Research ...
Expert Point of View: Mark Pegram, MD & Martine Piccart, MD, PhD
Formal discussant of the ado-trastuzumab emtansine plus pertuzumab trial, Mark Pegram, MD, Director of the Breast Cancer Program at Stanford Women’s Cancer Center and Co-Director of Stanford’s Molecular Therapeutics Program, Stanford, California, said that I-SPY 2 has several strengths. They...
Expert Point of View: Lillian L. Siu, MD, FASCO
“This is an important study,” said formal discussant Lillian L. Siu, MD, FASCO, Professor, University of Toronto Cancer Care Ontario Research Chair and medical oncologist at Princess Margaret Cancer Centre Drug Development Program in Toronto, Ontario, Canada. “No new drugs have been approved by the ...
Nivolumab: New Standard of Care for Progressive Head and Neck Cancer After Platinum Therapy
Squamous cell carcinoma of the head and neck that progresses after platinum-based therapy has a dismal prognosis, and there is no effective standard of care. No treatment has improved survival for this patient population, but that may be about to change. Nivolumab (Opdivo), an anti–PD-1 (programmed ...
Dethroning the Emperor of All Maladies
Deep knowledge of immunology, cancer biology, and disruptive technology in computational science and molecular profiling has positioned us to dethrone the emperor of all maladies. The cancer research community is prepared to fulfill President Barack Obama’s call for a national cancer moonshot aimed ...
Using Telemedicine to Reduce Wait Times for Veterans
John Farrow, a 67-year-old Vietnam veteran, had not been able to sleep for days. A week ago, his primary care doctor at his local outpatient Veterans Administration (VA) clinic told him that his prostate-specific antigen (PSA) blood level was rapidly increasing, and his prostate was abnormal on...
Making the Moonshot Initiative a Reality
Excitement was high on the last day of the 2016 Annual Meeting of the American Association for Cancer Research (AACR) in anticipation of Vice President Joseph R. Biden’s remarks related to the Moonshot Initiative to accelerate progress in cancer research. The Secret Service made elaborate...
One-Third of Patients With Advanced Melanoma Survive at Least 5 Years After Nivolumab Treatment
The news is good from the longest follow-up survival study of patients with advanced melanoma who were treated with the anti–programmed cell death protein 1 (PD-1) agent nivolumab (Opdivo).1 Thirty-four percent of patients who received the drug in a phase I trial (CA909-003) were alive 5 years...
Study Explores Differential Localization of Glioblastoma Subtypes and Pathogenesis
Researchers at the University of California San Diego School of Medicine have demonstrated that distinct types of glioblastoma tend to develop in different regions of the brain. This finding provides an explanation for how the same cancer-causing mutation can give rise to different types of brain...
Spectrin Gene Identified as a Biomarker in HPV-Negative Oral Cavity Squamous Cell Carcinoma
Researchers have identified a gene that may help to predict survival outcomes in patients with cancer of the mouth and tongue. Patients whose tumors express a gene called spectrin are 4.6 times more likely to die at any given time, according to a study by researchers at Loyola Medicine and Loyola...
Potential Targets for Loss of Appetite/Cachexia Related to Interleukin 18 Activity Identified in Early Studies
Loss of appetite during illness is a common and potentially debilitating phenomenon. In cancer patients especially, it can even shorten lifespan. Scientists at The Scripps Research Institute (TSRI) have discovered how an immune system molecule controls a brain circuit and reduces appetite. Their...
FDA Grants sBLA for Blinatumomab in Pediatric Patients With Ph–Negative Relapsed/Refractory B-Cell Precursor ALL
Amgen announced on May 3 that the U.S. Food and Drug Administration (FDA) has accepted for priority review the supplemental Biologics License Application (sBLA) for blinatumomab (Blincyto) to include new data supporting the treatment of pediatric and adolescent patients with Philadelphia...
Effects of High Residential Segregation and Neighborhood Characteristics on Early-Stage NSCLC Surgery
Black residents of highly segregated neighborhoods were less likely to receive surgery for early-stage non–small cell lung cancer (NSCLC) than their peers in less-segregated neighborhoods, according to a study published by Johnson et al in Cancer Epidemiology, Biomarkers & Prevention....
ESTRO 2016: New Study Sheds Light on Mastectomy vs Breast-Conserving Therapy in Older vs Younger Patients With Early Breast Cancer
New research presented at the ESTRO 35 Conference on April 30 (Abstract OC-0052) has shown women aged younger than 45 years with early-stage breast cancer that had not spread to the lymph nodes and who opted for breast-conserving therapy with radiation therapy had a 13% higher risk of developing a...
ESTRO 2016: Radiotherapy vs Chemotherapy in a Study of Patients With Early Stage II Testicular Cancer
A large study of testicular cancer patients showed that radiation therapy was more effective than chemotherapy for patients with stage IIa disease (where one or more regional lymph nodes contain cancer cells, but they are less than 2 cm in diameter). These findings, presented at the ESTRO 35...
Study Finds Cancer Mortality Risks From Long-Term Exposure to Ambient Fine Particulate Matter
Long-term exposure to ambient fine particulate matter, a mixture of environmental pollutants, was associated with increased risk of mortality for many types of cancer in an elderly Hong Kong population, according to a study published by Wong et al in Cancer Epidemiology, Biomarkers &...
ESTRO 2016: SBRT in Early-Stage Lung Cancer Linked to Increased Risk of Noncancer Deaths
Researchers have found that treating patients who have early-stage non–small cell lung cancer (NSCLC) with stereotactic body radiation therapy (SBRT) is associated with a small but increased risk of death from causes other than cancer, according to findings presented at the European Society...
ESTRO 2016: Radiation and L19-IL2 Immunotherapy Combination Shows Activity in Preclinical Models
Radiation therapy not only targets and destroys cancer cells, but also helps to activate the immune system against their future proliferation. However, this immune response is often not strong enough to be able to completely eradicate tumors, and even when it is, its effect is limited to the area...
ESTRO 2016: Failure to Publish Phase III Radiotherapy Trial Results Exposes Patients to Risks Without Providing Benefits for Others
Although the publication of results of clinical trials carried out in the United States within 12 months of their completion has been mandatory since 2007, a remarkably high number of phase III radiotherapy trials did not do so, according to new research presented at the European Society for...
Study Links Residential Radon Exposure to Increased Risk of Hematologic Malignancies in Women
A new report published by Teras et al in Environmental Researchfound a statistically significant, positive association between high levels of residential radon and the risk of hematologic cancer (lymphoma, myeloma, and leukemia) in women. The study is the first prospective, population-based study...
Study Finds No Association Between Anthracycline-Based Chemotherapy and Cognitive Decline in Women With Breast Cancer
A new study by University of California, Los Angeles (UCLA) researchers published by Van Dyk et al in JAMA Oncology found that commonly used chemotherapy drugs showed no association with cognitive decline following treatment in women with breast cancer. The report addresses recent concerns that the ...
New Study Suggests Cholesterol Levels, Not Statins, Influence Colorectal Cancer Risk
Long-term use of the cholesterol-lowering drugs statins does not appear to decrease a patient’s risk of colorectal cancer, suggests a new, large case-control study from Penn Medicine published by Mamtani et al in PLOS Medicine. The observational analysis of over 100,000 patients’...
ASCO Adapts CCO Guideline on Selection of Optimal Adjuvant Therapy for Breast Cancer
ASCO has adapted a Clinical Care Ontario (CCO) clinical practice guideline on the selection of optimal adjuvant chemotherapy for early breast cancer and adjuvant targeted therapy for HER2-positive breast cancer, as reported in the Journal of Clinical Oncology. The adaptation was based on review by...
Solid Organ Transplant Recipients With Preexisting Malignancies in Remission May Be More Likely to Die, Develop New Cancers
Patients who had cancer before receiving an organ transplant were more likely to die of any cause, die of cancer, or develop a new cancer than organ recipients who did not previously have cancer, a new study published by Acuna et al in the journal Transplantation has found. However, the increased...
